Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Hyoung-Chul | - |
dc.contributor.author | Cheon, Young Koog | - |
dc.contributor.author | Cho, Young Deok | - |
dc.contributor.author | Do, Jae Hyuk | - |
dc.date.available | 2019-05-29T11:36:31Z | - |
dc.date.issued | 2011-09 | - |
dc.identifier.issn | 0016-5107 | - |
dc.identifier.issn | 1097-6779 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21290 | - |
dc.description.abstract | Background: Udenafil, a phosphodiesterase-5 inhibitor, may decrease sphincter of Oddi tone and allow efficient cannulation. Objective: To determine whether prophylactic udenafil reduces the rates of occurrence of post-ERCP pancreatitis. Design: Prospective, randomized, double-blind, placebo-controlled, multicenter study. Setting: Three academic medical centers. Patients: From November 2008 to November 2010, a total of 278 patients who underwent ERCP were analyzed. Intervention: ERCP. Main Outcome Measurement: Rate of post-ERCP pancreatitis. Results: Demographic features, indications for ERCP, and therapeutic procedures were similar in each group. The overall rate of pancreatitis was 7.9% (22/278). There was no significant difference in the rate (8.0% [11/137] vs 7.8% [11/141], P = .944) and severity of post-ERCP pancreatitis between the udenafil and placebo groups. Severe pancreatitis developed in 1 patient in the placebo group. On both univariate and multivariate analyses, age 40 years or younger, suspected sphincter of Oddi dysfunction, complete pancreatic duct opacification, and failed cannulation were associated with post-ERCP pancreatitis. Only mild udenafil-related complications occurred, including flushing (n = 3) and headache (n = 3). Limitations: Unselected patient group, overestimation of the rate of pancreatitis in the placebo group. Conclusion: Udenafil was not effective for prevention of post-ERCP pancreatitis in this study. (Clinical trial registration number: KCT0000021.) (Gastrointest Endosc 2011;74:556-62.) | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MOSBY-ELSEVIER | - |
dc.title | Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.gie.2011.04.047 | - |
dc.identifier.bibliographicCitation | GASTROINTESTINAL ENDOSCOPY, v.74, no.3, pp 556 - 562 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000294660200015 | - |
dc.identifier.scopusid | 2-s2.0-80052266438 | - |
dc.citation.endPage | 562 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 556 | - |
dc.citation.title | GASTROINTESTINAL ENDOSCOPY | - |
dc.citation.volume | 74 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY | - |
dc.subject.keywordPlus | BILIARY SPHINCTEROTOMY | - |
dc.subject.keywordPlus | GLYCERYL TRINITRATE | - |
dc.subject.keywordPlus | TECHNICAL SUCCESS | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | SILDENAFIL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | CANNULATION | - |
dc.subject.keywordPlus | SEVERITY | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.